threonine has been researched along with Granulocytic Leukemia, Chronic in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, C; Li, P; Liu, N; Liu, Q; Ma, D; Sun, X; Zang, S | 1 |
| Digumarti, R; Gundeti, S; Kagita, S; Uppalapati, S | 1 |
| Fermeglia, M; Greco, A; Negri, T; Pavan, GM; Pierotti, MA; Pilotti, S; Pricl, S; Sandri, M; Tamborini, E; Virdis, E | 1 |
| Bertrand, A; Bonnet, ML; Brizard, F; Chomel, JC; Guilhot, F; Roy, L; Sorel, N; Turhan, AG | 1 |
| Ding, K; Leng, F; Li, Y; Long, H; Lu, X; Luo, J; Pan, X; Ren, X; Shen, M; Tu, Z; Wen, D; Zhang, F; Zhang, Z | 1 |
| Banger, N; Berdel, WE; Chou, TC; Kiehl, M; Koch, OM; Müller-Tidow, C; Probst, M; Serve, H; Sindermann, JR; Zühlsdorf, M | 1 |
| Fermeglia, M; Ferrone, M; Pricl, S; Tamborini, E | 1 |
| Tuma, RS | 1 |
| Baccarani, M; Iacobucci, I; Martinelli, G; Soverini, S | 1 |
9 other study(ies) available for threonine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.
Topics: Antineoplastic Agents; Apoptosis; Benzophenanthridines; Cell Differentiation; Down-Regulation; Drug Resistance, Neoplasm; Erythroid Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Phosphorylation; Proteolysis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc; Threonine | 2015 |
Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Threonine | 2015 |
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Topics: Antineoplastic Agents; Benzamides; Computer Simulation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Research Design; Threonine | 2009 |
Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.
Topics: Aged; Amino Acid Substitution; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; Genes, abl; Humans; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation, Missense; Myeloid Progenitor Cells; Neoplastic Stem Cells; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Threonine | 2010 |
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Structure; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Threonine | 2012 |
Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; DNA Fragmentation; Dose-Response Relationship, Drug; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon alpha-2; Interferon-alpha; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lovastatin; Mevalonic Acid; Phosphorylation; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Recombinant Proteins; Serine; Threonine; Time Factors; Tyrosine | 2003 |
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
Topics: Antineoplastic Agents; Benzamides; Computational Biology; Computer Simulation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Threonine | 2005 |
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; Dasatinib; Drug Administration Schedule; Drug Costs; Fusion Proteins, bcr-abl; HIV Infections; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Threonine; United States | 2007 |
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Benzene Derivatives; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Hydroxamic Acids; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Naphthalenes; Panobinostat; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Structure-Activity Relationship; Threonine; Vorinostat | 2007 |